Age
Item
age >18.
boolean
C0001779 (UMLS CUI [1])
Informed Consent
Item
be able to provide written consent to perform in the trial.
boolean
C0021430 (UMLS CUI [1])
HIV antibody positive
Item
hiv antibody positive at time of entry to the study.
boolean
C0920548 (UMLS CUI [1])
HIV Infections | Abnormality of metabolism | Clinical Trial Part
Item
specific to hiv infection and metabolic abnormalities protocol 1 (hama) part a only:
boolean
C0019693 (UMLS CUI [1])
C4021768 (UMLS CUI [2])
C0008976 (UMLS CUI [3,1])
C0449719 (UMLS CUI [3,2])
Therapy naive Anti-Retroviral Agents
Item
be naive to antiretroviral medication.
boolean
C0919936 (UMLS CUI [1,1])
C0599685 (UMLS CUI [1,2])
HIV Infections | Abnormality of metabolism | Clinical Trial Part
Item
specific to hama part b only:
boolean
C0019693 (UMLS CUI [1])
C4021768 (UMLS CUI [2])
C0008976 (UMLS CUI [3,1])
C0449719 (UMLS CUI [3,2])
Anti-Retroviral Agents Exposure to Duration Total Minimum
Item
have had a minimum total exposure to antiretroviral medications (to include drugs from more than one drug class) of 48 weeks at time of recruitment.
boolean
C0599685 (UMLS CUI [1,1])
C0332157 (UMLS CUI [1,2])
C0449238 (UMLS CUI [1,3])
C0439810 (UMLS CUI [1,4])
C1524031 (UMLS CUI [1,5])
Interval Since Clinical Trial Part Completion
Item
have had a minimum of 48 weeks interval since completion of hama part a.
boolean
C1272706 (UMLS CUI [1,1])
C1711239 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,3])
C0449719 (UMLS CUI [1,4])
C0205197 (UMLS CUI [1,5])
Mental disorders Study Subject Participation Status Limited | Physical Condition Study Subject Participation Status Limited | Myocardial Ischemia
Item
any history of, or ongoing, mental or physical condition (including suspected or known diagnosis of ischaemic heart disease), which, in the opinion of the investigator, would impede the subject's ability to participate in the trial.
boolean
C0004936 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C0439801 (UMLS CUI [1,3])
C3714565 (UMLS CUI [2,1])
C2348568 (UMLS CUI [2,2])
C0439801 (UMLS CUI [2,3])
C0151744 (UMLS CUI [3])
Growth Hormone | Glucocorticoids | Anabolic steroids
Item
prior use of growth hormone or glucocorticoid or anabolic steroid products within the previous six months.
boolean
C0037663 (UMLS CUI [1])
C0017710 (UMLS CUI [2])
C0002845 (UMLS CUI [3])
Testosterone Dose Very high | Estrogen Replacement Therapy
Item
prior use of supraphysiological doses of testosterone or oestrogen replacement therapy within the previous year.
boolean
C0039601 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0442804 (UMLS CUI [1,3])
C0014935 (UMLS CUI [2])
Substance Use Disorders Study Subject Participation Status Limited
Item
alcohol or substance abuse which in the opinion of the investigator would affect the patients ability to participate in the trial.
boolean
C0038586 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C0439801 (UMLS CUI [1,3])
Compound Containing Retinoids
Item
prior use of any retinoid-containing compound within the previous six months.
boolean
C1706082 (UMLS CUI [1,1])
C0332256 (UMLS CUI [1,2])
C0035339 (UMLS CUI [1,3])
Blood Coagulation Disorders
Item
abnormal coagulation.
boolean
C0005779 (UMLS CUI [1])
Allergic Reaction Local Anesthetics | Hypersensitivity Local Anesthetics
Item
previous allergic reaction or known allergy to local anaesthetic.
boolean
C1527304 (UMLS CUI [1,1])
C0002934 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0002934 (UMLS CUI [2,2])
Pharmaceutical Preparations Affecting Protocol Compliance
Item
previous or concomitant use of medications, which, in the opinion of the investigator, would affect the subject's ability to participate in all activities involved in the trial.
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0525058 (UMLS CUI [1,3])
Blood Screening LABORATORY ABNORMALITIES Grade | Protocol Compliance Limited
Item
any grade-three laboratory abnormality recorded from screening bloods, which, in the opinion of the investigator, would impede the subject's ability to safely complete all study requirements.
boolean
C1511226 (UMLS CUI [1,1])
C1853129 (UMLS CUI [1,2])
C0441800 (UMLS CUI [1,3])
C0525058 (UMLS CUI [2,1])
C0439801 (UMLS CUI [2,2])
screening examination Finding Study Subject Participation Status Limited
Item
any finding on screening clinical examination, which, in the opinion of the investigator, would impede the subject's ability to participate in the rest of the trial.
boolean
C0281974 (UMLS CUI [1,1])
C0243095 (UMLS CUI [1,2])
C2348568 (UMLS CUI [1,3])
C0439801 (UMLS CUI [1,4])
Pregnancy
Item
pregnancy
boolean
C0032961 (UMLS CUI [1])
HIV Infections | Abnormality of metabolism | Clinical Trial Part
Item
specific to hama part a only:
boolean
C0019693 (UMLS CUI [1])
C4021768 (UMLS CUI [2])
C0008976 (UMLS CUI [3,1])
C0449719 (UMLS CUI [3,2])
Anti-Retroviral Agents | Protease Inhibitors | Nucleoside Reverse Transcriptase Inhibitors | Non-Nucleoside Reverse Transcriptase Inhibitors | Anti-Retroviral Agents Investigational | Fusion inhibitor | Antiretroviral therapy | Post-Exposure Prophylaxis
Item
prior use of anti-retroviral agents (including protease inhibitors, nucleoside or non-nucleoside reverse transcriptase inhibitors, investigational antiretroviral agents or fusion inhibitors). entry of individuals who have had previous antiretroviral therapy as part of post exposure prophylaxis will be at the discretion of the study investigators.
boolean
C0599685 (UMLS CUI [1])
C0033607 (UMLS CUI [2])
C1373111 (UMLS CUI [3])
C1373120 (UMLS CUI [4])
C0599685 (UMLS CUI [5,1])
C1517586 (UMLS CUI [5,2])
C1275666 (UMLS CUI [6])
C1963724 (UMLS CUI [7])
C1443861 (UMLS CUI [8])